Is Jazz Pharmaceuticals plc’s (Jazz) stock going up?
The Jazz Pharmaceuticals plc stock price gained 0.95% on the last trading day (Friday, 4th Feb 2022), rising from $139.61 to $140.94. During the day the stock fluctuated 2.92% from a day low at $138.01 to a day high of $142.04. The price has risen in 6 of the last 10 days and is up by 3.06% over the past 2 weeks.
Is Jazz Inc’s (Jazz) earnings growth rate good for investors?
For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration. While the historical EPS growth rate for Jazz is 10.6%, investors should actually focus on the projected growth.
Where can I buy shares of jazz?
Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Will Jazz Pharmaceuticals (jazz) outperform or underperform the S&P 500?
MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals and other stocks. Vote “Outperform” if you believe JAZZ will outperform the S&P 500 over the long term. Vote “Underperform” if you believe JAZZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
Is Jazz Pharmaceuticals a good stock?
Jazz Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.
Why is Jazz Pharmaceuticals stock dropping?
The decline started during the summer when Jazz reported second-quarter earnings that showed sales of its top sleep disorder drug, Xylem, plunged 25% from the prior year. While that's because patients were being transitioned over to its next-generation drug, Xywav, combined sales were only 3% higher.
What happened JAZZ Pharma?
On September 19, 2011, Jazz Pharmaceuticals merged with Irish Azur Pharma plc to form Jazz Pharmaceuticals plc. The Azur Pharma seat in Dublin became the headquarters of the combined company.
Who buys JAZZ?
GW PharmaceuticalsJazz Pharmaceuticals (JAZZ 0.45%) and GW Pharmaceuticals are now under the same corporate roof. The two companies announced Wednesday that Jazz's acquisition of GW has been completed. This brings the $7.6 billion cash-and-stock deal, first announced in early February, to a close.
Will Jazz Pharmaceuticals stock go up?
The 17 analysts offering 12-month price forecasts for Jazz Pharmaceuticals PLC have a median target of 200.00, with a high estimate of 240.00 and a low estimate of 174.00. The median estimate represents a +25.84% increase from the last price of 158.93.
Will JAZZ stock go up?
Based on our forecasts, a long-term increase is expected, the "JAZZ" stock price prognosis for 2027-07-09 is 169.311 USD. With a 5-year investment, the revenue is expected to be around +9.96%. Your current $100 investment may be up to $109.96 in 2027.
Is Jazz Pharma publicly traded?
Announces Initial Public Offering. PALO ALTO, Calif., May 31 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 6,000,000 shares of common stock at $18.00 per share.
What is Jazz Pharma known for?
Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live their lives more fully.
Who did Jazz Pharmaceuticals merge with?
GW Pharmaceuticals plc3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for ...
Is Ryan Smith a billionaire?
Ryan Smith is an American billionaire businessman. He is the executive chairman and co-founder of Qualtrics, an experience management company based in Provo, Utah, United States. In 2016, he was included in Fortune's "40 Under 40".
Who owns the Jazz?
Ryan SmithUtah Jazz / OwnerRyan Smith was at the Vivint Arena in Salt Lake City, Utah right before our chat. “I was just watching the team warm up for tomorrow's game," he told me over the phone. Smith is the owner of the NBA's Utah Jazz, purchasing it from the Miller family in 2020 for a reported price tag of $1.66 billion.
How much did Jazz sell for?
$1.6 billionSmith bought the Jazz organization from the Miller family in October 2020 for an estimated cost of $1.6 billion.
Should I buy or sell Jazz Pharmaceuticals stock right now?
11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are curren...
What is Jazz Pharmaceuticals' stock price forecast for 2022?
11 analysts have issued 12-month price targets for Jazz Pharmaceuticals' stock. Their forecasts range from $174.00 to $250.00. On average, they ant...
How has Jazz Pharmaceuticals' stock performed in 2022?
Jazz Pharmaceuticals' stock was trading at $127.40 at the beginning of 2022. Since then, JAZZ stock has increased by 15.8% and is now trading at $1...
When is Jazz Pharmaceuticals' next earnings date?
Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast for...
How were Jazz Pharmaceuticals' earnings last quarter?
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) released its quarterly earnings data on Wednesday, May, 4th. The specialty pharmaceutical company reported $...
What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?
Jazz Pharmaceuticals updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of for the period. The company is...
Who are Jazz Pharmaceuticals' key executives?
Jazz Pharmaceuticals' management team includes the following people: Mr. Bruce C. Cozadd , Co-Founder, Chairman & CEO (Age 58, Pay $2.48M) ( Lin...
What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?
60 employees have rated Jazz Pharmaceuticals CEO Bruce C. Cozadd on Glassdoor.com . Bruce C. Cozadd has an approval rating of 92% among Jazz Pharm...
Who are some of Jazz Pharmaceuticals' key competitors?
Some companies that are related to Jazz Pharmaceuticals include Johnson & Johnson (JNJ) , Eli Lilly and (LLY) , Pfizer (PFE) , AbbVie (ABBV) ,...
When will Jazz Pharmaceuticals release its earnings?
How much does Jazz Pharmaceuticals make?
Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021. View our earnings forecast for Jazz Pharmaceuticals.
Nasdaq Global Select
Jazz Pharmaceuticals has a market capitalization of $9.86 billion and generates $2.36 billion in revenue each year. The specialty pharmaceutical company earns $238.62 million in net income (profit) each year or $10.77 on an earnings per share basis.
Environmental, Social, and Governance Rating
A specialty pharmaceutical company, which focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Signals & Forecast
A specialty pharmaceutical company, which focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.
Support, Risk & Stop-loss
Mostly positive signals in the chart today. The Jazz Pharmaceuticals plc stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.
Is Jazz Pharmaceuticals plc stock A Buy?
On the downside, the stock finds support just below today's level from accumulated volume at $125.29 and $122.41. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level.
Insiders are neutral as most recent trades are sells in Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
About Jazz Pharmaceuticals plc
In the last 100 trades there were 198.22 thousand shares bought and 187.31 thousand shares sold. The last trade was done 14 days ago by Cozadd Bruce C who sold 9.7 thousand shares. For the period there has been more stocks bought than sold among the insiders, but most of the latest transaction have been insiders selling.
Golden Star Signal
Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target and Consensus Rating
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Analyst Price Target Consensus
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Ratings By Month
Sign-up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Jazz Pharmaceuticals (NASDAQ:JAZZ) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
Who is the CEO of Jazz?
According to the issued ratings of 15 analysts in the last year, the consensus rating for Jazz Pharmaceuticals stock is Buy based on the current 1 hold rating and 14 buy ratings for JAZZ. The average twelve-month price target for Jazz Pharmaceuticals is $209.07 with a high price target of $250.00 and a low price target of $174.00.
Is Jazz a big mover?
In the companies' joint press release, Jazz CEO Bruce Cozadd was quoted as saying that the closing "mark [s] a transformative milestone in creating an innovative, high-growth, global biopharma leader in neuroscience with a worldwide commercial and operational footprint.". Zacks • 2 months ago.
